CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Doxycycline +1 moredrug
Likely dose
Doxycycline 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04860505
NCT04860505Phase 4Completed
CompareCT.gov

Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

Emory University·interventional·Posted Apr 27, 2021·Updated May 23, 2023

In Brief

A Phase 4 clinical trial evaluating Doxycycline and Biktarvy for Sexually Transmitted Diseases. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexually Transmitted Diseases
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedApr 27, 2021
Enrollment StartMay 20, 2021
Primary CompletionMay 9, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.2 years ago

Interventions

Doxycyclinedrug

Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.

Biktarvydrug

Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.